Know Cancer

or
forgot password

Vesicareā„¢ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy


N/A
18 Years
N/A
Open (Enrolling)
Male
Incontinence Post-robotic Prostatectomy

Thank you

Trial Information

Vesicareā„¢ (Solifenacin) in the Treatment of Urinary Incontinence After Radical Prostatectomy


Inclusion Criteria:



- Patients that have been diagnosed with prostate cancer and will undergo treatment for
the disease as part of standard clinical care

- Patients that have multiple pad use a few days after standard of care catheter
removal

Exclusion Criteria:

- Contra-indication to Solifenacin

- Narrow angle glaucoma

- Hepatic impairment

- Renal impairment

- CYP3A4 inhibitors (e.g. Ketoconazole)

- Gastric Retention (delayed or slow emptying of the stomach)

- Lives in a different country

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Time to Continence

Outcome Time Frame:

12 months

Safety Issue:

No

Authority:

United States: Institutional Review Board

Study ID:

2007-5720-2

NCT ID:

NCT01215721

Start Date:

October 2010

Completion Date:

September 2013

Related Keywords:

  • Incontinence Post-robotic Prostatectomy
  • Incontinence
  • Robotic Prostatectomy
  • Prostate Cancer
  • Urinary Incontinence

Name

Location

University of California, Irvine Medical CenterOrange, California  92868